Antibodies
11 October 2023
Temtokibart achieves First Subject First Treatment (FSFT) milestone in Phase 2b trial10 October 2023
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer10 October 2023
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)10 October 2023
CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region8 October 2023
FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases8 October 2023
FDA Approves TOFIDENCE™ (tocilizumab-bavi) a Biosimilar of ACTEMRA® developed by Bio-Thera Solutions4 October 2023
Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers4 October 2023
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial4 October 2023
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment2 October 2023
Adalimumab-adbm, Boehringer Ingelheim’s Interchangeable biosimilar to Humira®, now available at low wholesale acquisition cost2 October 2023
PD-1 Agonists: a pipeline review of an emerging class of novel agonist antibodies for treatment of autoimmune diseasesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports